| Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019 VN Giri, KE Knudsen, WK Kelly, HH Cheng, KA Cooney, MS Cookson, ... Journal of Clinical Oncology 38 (24), 2798-2811, 2020 | 230 | 2020 |
| Complement inhibition with eculizumab for thrombotic microangiopathy rescues a living-donor kidney transplant in a patient with antiphospholipid antibody syndrome PR Geethakumari, P Mille, R Gulati, S Nagalla Transfusion and Apheresis Science 56 (3), 400-403, 2017 | 16 | 2017 |
| Pretest genetic education video versus genetic counseling for men considering prostate cancer germline testing: a patient-choice study to address urgent practice needs J Russo, C McDougall, N Bowler, A Shimada, L Gross, C Hyatt, WK Kelly, ... JCO precision oncology 5, 1377-1386, 2021 | 13 | 2021 |
| Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for … S Loeb, HH Cheng, A Leader, L Gross, TS Nolasco, N Byrne, DR Wise, ... Contemporary Clinical Trials 119, 106821, 2022 | 5 | 2022 |
| A randomized phase Ib/II study of intermittent androgen deprivation therapy plus nivolumab with or without interleukin-8 blockade in men with hormone-sensitive prostate cancer … M Dallos, SM Pan, M Chaimowitz, MN Stein, EA Lim, J Hawley, N Sender, ... Journal of Clinical Oncology 40 (16_suppl), 5082-5082, 2022 | 4 | 2022 |
| Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer KK Zarrabi, V Narayan, PJ Mille, MR Zibelman, B Miron, B Bashir, ... Therapeutic Advances in Urology 15, 17562872231182219, 2023 | 3 | 2023 |
| TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing S Loeb, SW Keith, HH Cheng, AE Leader, L Gross, T Sanchez Nolasco, ... JCO Precision Oncology 8, e2300552, 2024 | | 2024 |
| Tumor-associated antigen targets for novel immune-based strategies in prostate cancer A Bhasin, P Mille, A Eturi, A Iskander, W Tester, K Zarrabi | | 2024 |
| Phase II, Single Arm, Open Label, Single Center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent B-Cell Non-Hodgkin Lymphomas N Kendsersky, R Masel, A Bhasin, T Zhan, C Gung, M George, FM Fellin, ... Blood 142, 3028, 2023 | | 2023 |
| Enhancing bladder cancer care through the multidisciplinary clinic approach JR Mark, LG Gomella, CD Lallas, KE Smentkowski, A Calvaresi, ... The Canadian Journal of Urology 30 (3), 11526-11531, 2023 | | 2023 |
| Technology-enhanced acceleration of germline evaluation for therapy (TARGET): Results of a randomized controlled trial of a pretest patient-driven webtool vs. genetic … VN Giri, SW Keith, HH Cheng, A Leader, L Gross, T Sanchez Nolasco, ... Journal of Clinical Oncology 41 (16_suppl), 10598-10598, 2023 | | 2023 |
| Sonoporation for disrupting the pancreatic cancer microenvironment to enhance chemotherapy delivery and improve outcomes. J Posey, P Machado, JR Eisenbrey, B Bashir, PJ Mille, A Basu Mallick, ... Journal of Clinical Oncology 41 (4_suppl), TPS777-TPS777, 2023 | | 2023 |
| Trial in Progress: Sonoporation for Disrupting the Pancreatic Cancer Microenvironment to Enhance Chemotherapy Delivery and Improve Outcomes J Posey, JR Eisenbrey, B Bashir, P Mille, AB Mallick, R Singla, ... | | 2023 |
| Metastatic Bladder Cancer and the Use of Cisplatin Chemotherapy P Mille, J Carsello Chemotherapy and Immunotherapy in Urologic Oncology: A Guide for the …, 2021 | | 2021 |
